These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9699658

  • 1. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
    Wahlberg K, Høyer-Hansen G, Casslén B.
    Cancer Res; 1998 Aug 01; 58(15):3294-8. PubMed ID: 9699658
    [Abstract] [Full Text] [Related]

  • 2. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
    Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Jänicke F.
    J Clin Invest; 1993 Nov 01; 92(5):2160-7. PubMed ID: 8227331
    [Abstract] [Full Text] [Related]

  • 3. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
    Sundfeldt K, Ivarsson K, Rask K, Haeger M, Hedin L, Brännström M.
    Anticancer Res; 2001 Nov 01; 21(1A):65-70. PubMed ID: 11299791
    [Abstract] [Full Text] [Related]

  • 4. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G.
    Clin Cancer Res; 2008 Sep 15; 14(18):5785-93. PubMed ID: 18794088
    [Abstract] [Full Text] [Related]

  • 5. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep 15; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 6. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F.
    Cancer Res; 1998 May 01; 58(9):1843-9. PubMed ID: 9581823
    [Abstract] [Full Text] [Related]

  • 7. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.
    Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, Illmensee K.
    Cancer Res; 2003 Nov 01; 63(21):7507-14. PubMed ID: 14612552
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D, Nicosia RF, Nicosia SV.
    Clin Cancer Res; 1999 Apr 01; 5(4):823-9. PubMed ID: 10213218
    [Abstract] [Full Text] [Related]

  • 9. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Høyer-Hansen G, Ring-Larsen H, Høgdall EV.
    Anticancer Res; 2004 Apr 01; 24(3b):1981-5. PubMed ID: 15274388
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V, Genazzani AR.
    Biomed Pharmacother; 2008 Apr 01; 62(6):373-7. PubMed ID: 18037256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Protein studies in cystic and peritoneal fluids of ovarian tumors with special reference to CEA].
    Briese V, Strache RR, Voss P, Kunze M, Büttner HH.
    Zentralbl Gynakol; 1988 Apr 01; 110(5):291-7. PubMed ID: 3376613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, van Schaik JH, Boonstra H, Sweep CG.
    Anticancer Res; 2002 Apr 01; 22(1A):275-82. PubMed ID: 12017303
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors].
    Strache RR, Göcze PM, Szábo DG, Büttner HH, Briese V, Kunze M, Csaba IF, Röpcke G.
    Zentralbl Gynakol; 1989 Apr 01; 111(11):749-54. PubMed ID: 2781888
    [Abstract] [Full Text] [Related]

  • 20. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E.
    Clin Cancer Res; 2001 Aug 01; 7(8):2396-404. PubMed ID: 11489818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.